Zotefoams plc (ZTF) — Investment Research Note

Executive summary

Zotefoams is a UK-listed specialty foams manufacturer that produces nitrogen-expanded polyolefin (AZOTE), high-performance polymer foams (ZOTEK) and T-FIT industrial insulation, selling globally into footwear (Nike is its largest customer), aerospace, transport, packaging and construction. Across the 2021–2026 filings, the group has grown revenue from ~£101m to a run-rate of ~£190m with adjusted PBT rising from ~£7m to a consensus £26.3m FY26, driven by the Nike ZoomX footwear ramp, HPP mix enrichment, and — most recently — the OKC acquisition and a strategic reset around a Vietnam facility and a Croydon restructuring 2026-08 interim; 2026-01 trading update. The single most important valuation question today is whether the FY29 ambition of >£230m revenue / >£40m operating profit is credible, because on those numbers the stock is materially undervalued; on FY26–27 consensus alone it is only modestly cheap.

Fair value estimate

• Range: 470p – 580p per share (implied market cap £232m – £286m), mid ~525p / £259m.
• Methodology: forward P/E cross-checked against a simplified DCF-lite on the FY29 ambition.
  • FY26 consensus adjusted PBT £26.3m; at ~19% tax and 49.3m shares gives adjusted EPS ~43p. Applying 11–13.5x forward P/E (in line with UK specialty-chemicals mid-caps with 2-year EPS CAGR ~15–20%) gives 470p–580p.
  • Sense-check on FY29 ambition (>£40m operating profit): net income ~£30m, EPS ~60–62p. Applying 12x and discounting back three years at 10% gives ~540p — consistent with the P/E-based range.
• Vs. current 445.5p / £219.6m mcap: upside to mid ~18%; upside to top of range ~30%; downside to low ~5%. View: modestly undervalued.

Sector context

• Sector: Basic Materials / Chemicals (Specialty). Confirmed.
• Quality/growth/leverage vs peers: Above-average growth (organic +6% cc plus M&A) and above-average moat in nitrogen-expansion process technology; balance sheet is stronger than most UK specialty chemicals (0.98x covenant leverage, £50m headroom, £90m RCF refinanced Jan 2026 2026-08 interim). Margins (17% adjusted operating margin H1 26) are broadly in line with premium specialty chemicals.
• Comparable UK listed peers: Victrex (PEEK polymers), Synthomer (specialty polymers), Filtronic (niche specialist) — Victrex is the closest analogue in terms of proprietary specialty polymer tech and single-customer exposure profile.

Investment thesis

1. Structural earnings step-up already underway: adjusted PBT has more than tripled (£7m FY21 → £21m FY25 → £26m FY26E), driven by the ZoomX footwear ramp, HPP mix and North America operating gearing (H1 26 NA operating margin jumped from 8.3% to 17.6% on the second low-pressure vessel) 2026-08 interim.
2. Vietnam + Croydon restructuring is a self-help profit lever independent of end-market growth: the Vietnam facility (trial production Oct 2026) plus proposed Croydon restructuring (£4m annualised savings, <1yr payback) reposition the UK site around higher-margin non-footwear applications while relocating high-volume 3D preform footwear to a lower-cost, customer-proximate base 2026-08 interim.
3. OKC acquisition proof-points the "Expanding Beyond the Core" M&A pipeline: bought Nov 2025 at ~7x 2024 EBITDA, contributing £14.8m of revenue in its first full half, earnings-accretive, ahead of plan, and adds recycled-foam capability — a template for further disciplined M&A within a still-strong balance sheet 2025-11 acquisition RNS; 2026-08 interim.

Key risks

1. Concentration in one footwear customer (Nike): HY26 sales to a single EMEA customer were £28.5m — about 30% of group revenue — and are set to fall further through the Vietnam transition (H2 26 and 2027 footwear will be weaker before "recovering from 2028") 2026-08 interim. Loss of, or step-down in, this relationship would be materially damaging.
2. Execution risk on Vietnam start-up + UK restructuring simultaneously: management explicitly flags "temporary inefficiency" from dual UK/Vietnam production and material one-off restructuring costs (H2 26); footwear profitability is expected to "temporarily moderate" 2026-08 interim. History across UK specialty industrials shows such transitions often overshoot on cost and undershoot on ramp.
3. Raw material and energy cost inflation with limited pricing power in Polyolefin Foams: gross margin at 35.6% remains structurally lower than pure-play specialty peers and the business has already relied on Middle-East-linked surcharges 2026-08 interim; a sustained polymer price spike combined with weak industrial demand would compress the ~£20-40m fixed-cost absorption base.

Operating leverage

Zotefoams is a moderately fixed-cost, asset-heavy business. H1 26 shows the mechanics clearly: revenue +23% and adjusted operating profit +34% (adjusted operating margin 15.8% → 17.1%), so contribution margin on incremental sales is meaningfully above the running margin. Management discloses a contribution margin of 60.6% in H1 26 (vs. 59.4% HY25) 2026-08 interim — i.e. ~60p of every incremental £1 of revenue drops to gross profit before SG&A. With SG&A already scaled for the OKC acquisition and Vietnam/Korea build-out, and with two new capacity units (US low-pressure vessel now fully operational, Vietnam coming online), a 10–20% revenue beat above the £190m FY26 base would plausibly add ~£10–20m of gross profit, of which £6–12m could reach operating profit — i.e. a 25–50% profit surprise on a 15% revenue surprise. This is meaningful but not "software-like": Zotefoams is not a 100–200% profit-uplift name because c.60% of costs are variable. The clearest inflection points are (a) Vietnam ramp reaching design utilisation (2028+), and (b) the £4m Croydon cost-out on unchanged UK volumes.

Value-trap signals

None identified of the "cheap for a structural reason" variety. Modest cautions worth noting: single-customer concentration (Nike ~30% of revenue) and a large step-down in that customer's H2 26 / 2027 volumes; H1 26 free cash flow was a small outflow (£0.4m) due to WC build and acquisition consideration payments, though this is transitional. Debt has risen but leverage remains conservative at 0.98x with £50m headroom. Dividend has grown modestly every period (5.2% interim increase in H1 26) — no signs of pressure.

Earnings vs. expectations

The disclosure pattern shows a company that has consistently beaten or matched expectations over the past two years:

• FY23 (Jan 2024 update): adjusted PBT £13.1m vs. consensus £12.5m — ~5% beat.
• FY24 (Jan 2025 update): adjusted PBT £15.6m vs. consensus £14.9m — modest beat; revenue slightly ahead.
• HY25 (Aug 2025 interims): Board raised full-year underlying PBT guidance ahead of consensus £19.4m after H1 PBT of £11.4m (+37% YoY).
• FY25 (Jan 2026 update): adjusted PBT £21.1m vs. consensus £20.5m — beat; revenue £158.5m vs. £155.2m — slight beat.
• HY26 (Aug 2026): full-year expectations "unchanged" (i.e. in line) at £190.8m revenue / £26.3m adjusted PBT.

Pattern: more beats than in-lines, with management guiding conservatively then upgrading intra-year. Recent H1 26 language is more cautious ("cognisant of wider macroeconomic uncertainty") but underlying execution has been reliably ahead.

Conviction

4 — high. Anchoring factors: (a) clean, well-reviewed disclosure with clearly bridged adjusted vs. statutory metrics; (b) consistent 2-year track record of meeting or slightly beating guidance/consensus; (c) explicit medium-term ambition (FY29: >£230m revenue / >£40m operating profit) that can be triangulated with current run-rate. Limiting factors: (a) Vietnam ramp and Croydon restructuring create a wider FY27 outcome distribution than usual; (b) very high Nike dependency means the fair-value range depends materially on that customer's programme decisions, which are not disclosed with any granularity.